Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center
Articles
Takeaways on Treatment of Early-Stage NSCLC
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale;Ticiana Leal, MD, University of Wisconsin-Madison;Jarushka Naidoo, MBBCh, Beaumont Hospital;Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center;Jun Zhang, MD, PhD, University of Kansas Medical Center
October 26th 2020Read More
Risk of Pneumonitis Post-Chemoradiation in Stage 3 NSCLC
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale;Ticiana Leal, MD, University of Wisconsin-Madison;Jarushka Naidoo, MBBCh, Beaumont Hospital;Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center;Jun Zhang, MD, PhD, University of Kansas Medical Center
October 26th 2020Read More
Considering PD-L1 and EGFR Status With I/O in Stage 3 NSCLC
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale;Ticiana Leal, MD, University of Wisconsin-Madison;Jarushka Naidoo, MBBCh, Beaumont Hospital;Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center;Jun Zhang, MD, PhD, University of Kansas Medical Center
October 26th 2020Read More
PACIFIC Trial in Stage 3 NSCLC
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale;Ticiana Leal, MD, University of Wisconsin-Madison;Jarushka Naidoo, MBBCh, Beaumont Hospital;Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center;Jun Zhang, MD, PhD, University of Kansas Medical Center
October 26th 2020Read More
Future of Neoadjuvant I/O in ES NSCLC
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale;Ticiana Leal, MD, University of Wisconsin-Madison;Jarushka Naidoo, MBBCh, Beaumont Hospital;Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center;Jun Zhang, MD, PhD, University of Kansas Medical Center
October 26th 2020Read More
Neoadjuvant I/O for ES NSCLC: Key Trials from ESMO 2020
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale;Ticiana Leal, MD, University of Wisconsin-Madison;Jarushka Naidoo, MBBCh, Beaumont Hospital;Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center;Jun Zhang, MD, PhD, University of Kansas Medical Center
October 26th 2020Read More
Key Trials in Neoadjuvant I/O for ES NSCLC
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale;Ticiana Leal, MD, University of Wisconsin-Madison;Jarushka Naidoo, MBBCh, Beaumont Hospital;Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center;Jun Zhang, MD, PhD, University of Kansas Medical Center
October 26th 2020Read More
Role of Neoadjuvant I/O in ES NSCLC
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale;Ticiana Leal, MD, University of Wisconsin-Madison;Jarushka Naidoo, MBBCh, Beaumont Hospital;Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center;Jun Zhang, MD, PhD, University of Kansas Medical Center
October 26th 2020Read More
Patient Selection: Adjuvant Therapy and Testing for ES NSCLC
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale;Ticiana Leal, MD, University of Wisconsin-Madison;Jarushka Naidoo, MBBCh, Beaumont Hospital;Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center;Jun Zhang, MD, PhD, University of Kansas Medical Center
October 26th 2020Read More
Phase 3 ADAURA Study: EGFR-Mutated NSCLC
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale;Ticiana Leal, MD, University of Wisconsin-Madison;Jarushka Naidoo, MBBCh, Beaumont Hospital;Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center;Jun Zhang, MD, PhD, University of Kansas Medical Center
October 26th 2020Read More
Role of Postoperative Radiotherapy in Early Stage NSCLC
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale;Ticiana Leal, MD, University of Wisconsin-Madison;Jarushka Naidoo, MBBCh, Beaumont Hospital;Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center;Jun Zhang, MD, PhD, University of Kansas Medical Center
October 26th 2020Read More
Neoadjuvant Chemotherapy in Early-Stage NSCLC
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale;Ticiana Leal, MD, University of Wisconsin-Madison;Jarushka Naidoo, MBBCh, Beaumont Hospital;Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center;Jun Zhang, MD, PhD, University of Kansas Medical Center
October 26th 2020Read More
Treatment of Early-Stage NSCLC: Current Standard of Care
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale;Ticiana Leal, MD, University of Wisconsin-Madison;Jarushka Naidoo, MBBCh, Beaumont Hospital;Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center;Jun Zhang, MD, PhD, University of Kansas Medical Center
October 26th 2020Read More
Latest Updated Articles
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
